Revenue UCB on all time high (consensus analysts)

Based on the analyst's estimates both the revenue and the net profit would be on the highest levels in years. For this year most of the analyst expect a total sales of 4,05 billion euros. The expectations would mean a record revenue for the company. This is slightly more than the 2015's revenue of 3,88 billion euros.

Historical revenues and results UCB plus taxations 2016


For 2016 the analysts expect a record net profit of 533 million euros. For the current year the consensus of the result per share is a profit of 2,85 euros. Based on the analyst's expectations the price/earnings-ratio is 24,7.

Per share a dividend of 1,26 euros is expected. The dividend yield consequently equals 1,79 percent. The average dividend of the pharmaceutical company equals a rather low percent.

Based on the number of outstanding shares UCB 's market capitalization equals 13,25 billion euros.

At 11.54 the stock traded at 0,1 percent lower at 70,39 euros. News Wire & Equity Research: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.